GenFleet Therapeutics (Shanghai) Inc. (hereinafter referred to as GenFleet Inc.) has officially released an updated version of its Articles of Association, effective October 21, 2025. The document outlines key aspects of corporate governance, share structure, and management oversight.

GenFleet Inc. discloses that its total issued share capital stands at 370,366,630 shares upon listing in Hong Kong. The company’s registered capital is recorded at RMB 37.036663 million. The shares comprise both unlisted shares and no more than 102,633,800 H Shares, which were listed on the Hong Kong Stock Exchange on September 19, 2025.

According to the document, the Board holds the authority to convene general meetings, propose profit distribution plans, and decide on matters such as appointments of senior management officers. Meanwhile, the supervisory committee is empowered to oversee the company’s financial reporting, ensure directors and executives fulfill their duties, and address any issues related to overall compliance and accountability.

The articles also define statutory reserve requirements and procedures for corporate actions, including merger, spin-off, and dissolution. Shareholders’ rights and responsibilities are laid out in detail, highlighting obligations such as subscribing for shares and rights to inspect the company’s financial records and vote on major decisions.

This announcement reflects GenFleet Inc.’s efforts to align its governance framework with relevant laws and regulations, offering shareholders and stakeholders a clearer understanding of its internal operating rules. The newly effective Articles of Association serve as a key reference for the company’s corporate structure, shareholder rights, and management accountability going forward.